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ABSTRACT Highly pathogenic inﬂuenza A viruses (IAV) from avian hosts were ﬁrst
reported to directly infect humans 20 years ago. However, such infections are rare
events, and our understanding of factors promoting or restricting zoonotic transmis-
sion is still limited. One accessory protein of IAV, PB1-F2, was associated with patho-
genicity of pandemic and zoonotic IAV. This short (90-amino-acid) peptide does not
harbor an enzymatic function. We thus identiﬁed host factors interacting with H5N1
PB1-F2, which could explain its importance for virulence. PB1-F2 binds to HCLS1-
associated protein X1 (HAX-1), a recently identiﬁed host restriction factor of the PA
subunit of IAV polymerase complexes. We demonstrate that the PA of a mammal-
adapted H1N1 IAV is resistant to HAX-1 imposed restriction, while the PA of an
avian-origin H5N1 IAV remains sensitive. We also showed HAX-1 sensitivity for PAs
of A/Brevig Mission/1/1918 (H1N1) and A/Shanghai/1/2013 (H7N9), two avian-origin
zoonotic IAV. Inhibition of H5N1 polymerase by HAX-1 can be alleviated by its
PB1-F2 through direct competition. Accordingly, replication of PB1-F2-deﬁcient H5N1
IAV is attenuated in the presence of large amounts of HAX-1. Mammal-adapted
H1N1 and H3N2 viruses do not display this dependence on PB1-F2 for efﬁcient repli-
cation in the presence of HAX-1. We propose that PB1-F2 plays a key role in zoo-
notic transmission of avian H5N1 IAV into humans.
IMPORTANCE Aquatic and shore birds are the natural reservoir of inﬂuenza A vi-
ruses from which the virus can jump into a variety of bird and mammal host spe-
cies, including humans. H5N1 inﬂuenza viruses are a good model for this process.
They pose an ongoing threat to human and animal health due to their high mortal-
ity rates. However, it is currently unclear what restricts these interspecies jumps on
the host side or what promotes them on the virus side. Here we show that a short
viral peptide, PB1-F2, helps H5N1 bird inﬂuenza viruses to overcome a human re-
striction factor of the viral polymerase complex HAX-1. Interestingly, we found that
human inﬂuenza A virus polymerase complexes are already adapted to HAX-1 and
do not require this function of PB1-F2. We thus propose that a functional full-length
PB1-F2 supports direct transmission of bird viruses into humans.
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Highly pathogenic avian inﬂuenza A viruses (IAV) pose a continuing threat to humanand animal health and bear the potential for new inﬂuenza pandemics. Since 2003,
860 conﬁrmed cases of human H5N1 IAV have been reported to the WHO (1), with an
estimated mortality rate of about 50%. In the same time frame, millions of domestic
birds were culled or died as a consequence of H5N1 IAV infection, resulting in a
substantial economic burden (2).
Avian inﬂuenza viruses face tremendous challenges when overcoming the species
barrier to replicate in mammalian hosts. In fact, aside from limited family cluster
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infections (3), there are currently no examples of continuous human-to-human trans-
mission for the H5N1 subtype, despite a very high capacity of the virus to acquire
adaptive mutations. The reasons for this threshold of adaptation to the human hosts
can be interpreted as a poor adjustment to proviral host factors, an increased sensitivity
to host restriction factors, or a combination of the two. The viral RNA-dependent RNA
polymerase complex of avian IAV seems to require a number of host-speciﬁc adapta-
tions to function fully in mammalian cells. It is largely unclear which factors deﬁne a
successful zoonotic avian IAV. One viral protein which has repeatedly been proposed to
contribute to pathogenicity and lethality of pandemic and zoonotic IAV is PB1-F2 (4–8).
This short viral peptide is encoded from a 1 open reading frame (ORF) of segment 2.
Full-length PB1-F2 is predominantly found in viruses of avian origin (9), suggesting that
its natural function evolved in these host species. Consequently, full-length PB1-F2
ORFs were found in all pandemic viruses of avian origin and in zoonotic, highly
pathogenic avian IAV. The presence of a full-length PB1-F2 and certain sequence
variations in its C terminus has been associated with increased viral pathogenicity and
immune modulation (10, 11). However, depending on the investigated strain and the
cellular context, PB1-F2 can either promote or suppress antiviral signaling (11, 12). In
human hosts, H1N1 IAV descending from the 1918 Spanish inﬂuenza virus have the
full-length PB1-F2 ORF; however, from the late 1940s, it becomes truncated after 59
amino acids (aa) (9). H1N1 IAV descending from the 2009 swine ﬂu IAV carry an even
shorter PB1-F2 due to a premature STOP codon (13). Among human H3N2 strains, a
comparative study showed effects of PB1-F2 on viral pathology only in isolates recov-
ered directly after the introduction into the human population, while in later isolates
PB1-F2 seems to play only a minor role due to mutations or truncations (5, 10, 14).
Taken together, these ﬁndings imply that PB1-F2 could have an impact on the human
host in viruses recently derived from avian hosts, e.g., during a direct zoonotic infection
of humans with avian H5N1 strains.
Intriguingly, PB1-F2 does not contain an intrinsic enzymatic function and thus likely
depends on recruitment of host factors to evoke a phenotype during virus infection. In
this study, we identiﬁed novel host proteins interacting with PB1-F2 of a zoonotic H5N1
IAV in the context of viral infection. We found that PB1-F2 binds to and colocalizes with
HCLS-1-associated protein 1 (HAX-1), a poorly characterized restriction factor of IAV
polymerase function which binds to the PA subunit (15). Interestingly, HAX-1 robustly
restricts H5N1 polymerase function by targeting PA, while H1N1 PA promotes resis-
tance to HAX-1-dependent inhibition. We demonstrate that PB1-F2 of H5N1 IAV
balances the HAX-1-mediated restriction of PA by direct competition, thus allowing
these zoonotic viruses to successfully replicate in human hosts.
RESULTS
Identiﬁcation of host interaction partners of PB1-F2. Full-length PB1-F2 is pre-
dominantly maintained in avian isolates. Mutations and/or truncations occur in the
process of adaptation to mammalian hosts. In order to test the role of PB1-F2 at the
human-bird interface, we decided to use PB1-F2 from a human H5N1 isolate (A/Viet
Nam/1203/2004 [VN/1203]). This highly pathogenic avian-origin virus was isolated from
a human patient after infection from an avian host (16, 17) and thus provides a good
model to study the function of accessory viral proteins involved in overcoming species
barriers. To avoid the inconvenience of biosafety level 3 (BSL3) lab work, we chose a
low-pathogenicity mutant lacking the multibasic cleavage site (18). We ﬁrst generated
a PB1-F2-deﬁcient virus by taking advantage of reverse genetics, applying a strategy
proposed by Tauber and colleagues (19). We introduced two stop codons (see Materials
and Methods) that abolish expression of PB1-F2 (VN/1203 ΔF2) (Fig. 1a) without
affecting the amino acid sequence encoded by the PB1 ORF. In order to identify host
proteins binding to PB1-F2 during infection, we reconstituted this virus, VN/1203 ΔF2,
by infecting HEK 293T cells (293T cells) expressing N-terminally Flag-tagged PB1-F2 of
VN/1203. Proteins interacting with PB1-F2 were identiﬁed after Flag-speciﬁc pulldown
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and mass spectrometry (Fig. 1b; see also Tables S1 and S2 in the supplemental
material).
We found HCLS1-associated protein X-1 (HAX-1) among the top 10 host proteins
interacting with VN/1203 PB1-F2. This protein was recently described to bind to
inﬂuenza A virus (A/WSN/1933) PA and prevent it from entering the nucleus, thus
reducing viral transcription and replication (15). We postulated that PB1-F2 of avian IAV
might counteract this inhibition and decided to study the interaction of HAX-1 and
PB1-F2 in more detail.
The PB1-F2 C terminus interacts with HAX-1. In order to gain insight into the
interaction of PB1-F2 with HAX-1, we ﬁrst conﬁrmed the mass spectrometry data in
independent immunoprecipitation (IP) experiments. We tested PB1-F2 of VN/1203 and
of H1N1 A/Puerto Rico/8/1934 (PR/8) and showed that they both efﬁciently pulled
down HAX-1 (Fig. 2a).
We then tested which portion of PB1-F2 binds to HAX-1 and constructed a
C-terminally truncated version (aa 1 to 50) and an N-terminally truncated version (aa 40
to 90) of PB1-F2. Only the N-terminally truncated PB1-F2 construct pulled down HAX-1
efﬁciently, locating the interaction domain to the C-terminal region of PB1-F2 (Fig. 2a).
It is noteworthy that PB1-F2 consistently pulled down endogenous HAX-1 (Fig. 2b).
However, we could not determine with conﬁdence the domain for interaction of HAX-1
with full-length PB1-F2. Both the N-terminal portion and the C-terminal portion of
HAX-1 were less stably expressed than the full length, and only the N-terminal part
pulled down with PB1-F2. Of note, the C-terminal portion was even less stable, which
might explain its efﬁcient pulldown (Fig. 2c). By confocal immunoﬂuorescence (IF), we
conﬁrmed that VN/1203 and PR/8 PB1-F2 colocalize with HAX-1. Interestingly, VN/1203
PB1-F2 diffuses in the cytoplasm when expressed alone, while it focuses to punctate
structures in the presence of HAX-1, supporting an interaction of PB1-F2 with HAX-1
(Fig. 2d). Meanwhile, PR/8 PB1-F2 localizes to punctate structures independently of
HAX-1. The HAX-1 protein was described to localize predominantly to mitochondria
and partially to the endoplasmic reticulum (ER). Using ﬂuorescent proteins addressed
either to the mitochondria or to the ER, we conﬁrmed that PB1-F2 of VN/1203 and
HAX-1 colocalize at the mitochondria but not at the ER (Fig. 3). Finally, we tested the
interaction of PB1-F2 with HAX-1 in a bimolecular ﬂuorescence complementation (BiFC)
system, where proximal proteins coupled to one portion of a split yellow ﬂuorescent
protein (YFP) result in formation of an excitable ﬂuorophore (20). Interaction of YN-
PB1-F2 with YC-HAX-1 and YC-PB1-F2 with YN-HAX resulted in a strong YFP signal,
indicating close proximity of both proteins (Fig. 2e). Of note, we could not reproduce
FIG 1 Identiﬁcation of PB1-F2 interactors. (a) Western blot showing the efﬁcacy of PB1-F2 deletion in VN/1203. MDCK cells were infected at an
MOI of 5 and lysed 24 h postinfection. Lysates were processed through Western blotting for detection of the cellular protein actin and the viral
proteins NP (nucleoprotein) and PB1-F2. (b) Table showing the top 15 interactors identiﬁed by mass spectrometry.
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FIG 2 PB1-F2 and HAX-2 interact in coimmunoprecipitation and colocalize in IF. (a to c) 293T cells were transfected with each
indicated protein cloned into the mammalian expression plasmid pCAGGS. Whole-cell lysates (WCLs) were collected 24 h later
(Continued on next page)
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the mitochondrial localization of this interaction in this assay, likely because PB1-F2 is
as big as the split-YFP tag, which might cause subcellular misallocation.
PB1-F2-deﬁcient viruses are sensitive to inhibition by HAX-1. We postulated
that PB1-F2 could be required to overcome HAX-1-dependent inhibition of the viral
polymerase complex. Hsu and colleagues recently showed a 2-fold reduction of viral
titers of A/WSN/1933 H1N1 in control H1299 lung epithelial cells compared to HAX-1
short hairpin RNA (shRNA) knockdown H1299 cells (15). We decided to use a clustered
regularly interspaced short palindromic repeat (CRISPR)/Cas9 knockout (KO) approach
to fully remove endogenous HAX-1 from A549 lung epithelial cells and complemented
this approach with a HAX-1-overexpressing cell line (Fig. 4a). We could thus test the
sensitivity of PB1-F2-expressing and PB1-F2-deﬁcient viruses in the presence of various
levels of HAX-1. In the presence of high levels of HAX-1, we found reduced replication
only of the zoonotic H5N1 strain. This reduction was more pronounced in the virus
lacking PB1-F2 (VN/1203 ΔF2) than in the wild-type (wt) virus. In contrast, replication of
the H1N1 mammalian IAV strain did not appear to depend on PB1-F2 and replicated
efﬁciently in cells expressing high levels of HAX-1 (Fig. 4b). In cells lacking HAX-1
expression, we could observe a general increase of viral titer independent of the virus
strain or the presence/absence of PB1-F2 (Fig. 4c). Of note, we observed consistently a
reduction of viral titers for VN/1203 ΔF2 compared to wt virus in control cells. However,
this reduction did not reach statistical signiﬁcance. To further demonstrate that en-
dogenous levels of HAX-1 already impact the PB1-F2-deﬁcient H5N1 virus, we com-
pared viral protein expression in A549 wt cells. After 8 h and 24 h, VN/1203 ΔF2-infected
A549 wt cells contained lower levels of viral matrix protein M1 than did VN/1203
wt-infected cells (Fig. 4d). In accordance with the viral growth curves, there was no
difference in M1 levels of VN/1203 wt- and VN/1203 ΔF2-infected HAX-1-deﬁcient
cells. For PR/8, we rather found increased levels of M1 in case of VN/1203 ΔF2, a
phenomenon that does not correlate with the viral growth curves and currently
lacks explanation.
Taken together, these data suggest that HAX-1 indeed poses a speciﬁc barrier to
zoonotic avian viruses for replication in human cells and that PB1-F2 is required to
overcome this barrier.
Inhibition of virus replication does not correlate with apoptosis. HAX-1 was
shown to have antiapoptotic functions (21); thus, we tested if IAV infection induces
different levels of apoptosis in HAX-1 ctrl and HAX-1 KO A549 cells (Fig. 5a). In contrast
to the study by Hsu et al. (15), all viruses induced more apoptosis in HAX-1-deﬁcient
cells, with no signiﬁcant difference between wt and ΔF2 variants. We speculate that
increased apoptosis might enhance release of viral ribonucleoprotein complexes, con-
tributing to the overall increased virus titers in HAX-1 KO cells, as demonstrated before
(22). In A549 cells overexpressing HAX-1, we did not observe reduced apoptosis
compared to that in A549 wt cells (Fig. 5b). This rules out an impact of apoptotic cell
death on reduced virus replication in cells expressing high levels of HAX-1.
HAX-1 inhibits viral polymerase of avian viruses.We used a mini-replicon system
to corroborate the speciﬁc inhibitory effect of HAX-1 on avian IAV polymerase com-
plexes. A549 HAX-1 KO cells were transfected with increasing amounts of expression
plasmids for HAX-1 as well as the three subunits of the IAV polymerase, the IAV
nucleoprotein, and a luciferase reporter under the control of the IAV promoter
sequence. In the case of H5N1 polymerase, we observed a signiﬁcant and dose-
dependent reduction of viral polymerase-driven reporter gene production. The same
FIG 2 Legend (Continued)
and processed through regular IP (b) or sequential IP (a and c) using a monoclonal antibody against Flag-tagged proteins.
Samples were then analyzed by Western blotting. (d) HeLa cells were transfected with V5-HAX-1 and Flag-PB1-F2 proteins. Cells
were ﬁxed at 48 h, processed for detection of HAX-1 (red) and PB1-F2 (green) by immunoﬂuorescence, and stained with DAPI.
(e) YN and YC fragments of YFP were cloned at the N terminus or C terminus of glutathione S-transferase (GST; self-interacting
control), HAX-1, and VN.PB1-F2. HeLa cells were transfected with indicated combinations of those constructs and incubated for
40 h at 37°C and then 4 h at 33°C. Images were taken using the EVOS cell imaging system.
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FIG 3 PB1-F2 interacts with HAX-1 at the level of the mitochondria. (a and b) HeLa cells were transfected with V5-HAX-1 and
Flag-PB1-F2 proteins with an mTurquoise ﬂuorescent protein addressed either to the mitochondria (mitoT.) (a) or to the
endoplasmic reticulum (ERT.) (b). Cells were ﬁxed at 48 h and processed for detection of HAX-1 (red) and PB1-F2 (green) by
immunoﬂuorescence.
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FIG 4 HAX-1 inhibits virus replication in a PB1-F2-dependent manner. (a) Western blot showing the
efﬁciency of HAX-1 knockout and HAX-1 overexpression in the cells used for the growth curve. (b and
c) Different A549 cell lines were infected at an MOI of 0.01 with either VN/1203 wt, VN/1203 ΔF2, PR/8
wt, or PR/8 ΔF2 virus with TPCK-treated trypsin at 0.1 g/ml. Supernatants were collected at the
indicated time point postinfection, and virus titer was assessed by plaque assay on MDCK cells. Bars
represent means (n  3), with error bars indicating SDs. Fold changes between wt and ΔF2 viruses are
(Continued on next page)
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effect was observed in HAX-1-deﬁcient 293T and H1299 cells complemented with
different doses of exogenous HAX-1 (Fig. 6a). In contrast, the H1N1 polymerase function
was not affected (Fig. 6b). To demonstrate that PA and not another subunit of the
polymerase complex is the target of HAX-1-mediated inhibition, we replaced the H5N1
PA subunit with the H1N1 PA subunit while maintaining the residual components of
the H5N1 mini-replicon system. We observed that the H5N1 polymerase sensitivity to
HAX-1 was overcome by introduction of an H1N1 PA subunit (Fig. 6c). This result shows
that H5N1 PA is the target of HAX-1 function. In agreement with this, replacement of
H1N1 PA by H5N1 PA in the H1N1 mini-replicon renders the polymerase complex
susceptible to HAX-1 inhibition (Fig. 6c, right). Next we tested the sensitivity of PAs
from two additional avian-origin viruses which were shown to directly infect humans
(A/Brevig Mission/1/1918 H1N1 and A/Shanghai/1/2013 H7N9). The two PAs showed
equal sensitivities to HAX-1 in the context of the VN polymerase complex (Fig. 6d).
Finally, we tested a recent human H3N2 strain for its sensitivity to HAX-1. In contrast to
prepandemic and current human H1N1 strains, human H3N2 viruses carry a full-length
PB1-F2 ORF. The PA subunit of this virus was incompatible with the H5N1 mini-replicon
system and yielded only background luciferase signals, even in the absence of HAX-1
(data not shown). We thus decided to rescue a PB1-F2-deﬁcient mutant of this virus and
compare it to the parental strain. Deletion of PB1-F2 does not affect replication of H3N2
IAV independently of the HAX-1 levels of the host cell (Fig. 6e). From these results, we
conclude that PA subunits of zoonotic viruses are sensitive to HAX-1-dependent
FIG 4 Legend (Continued)
indicated in the table below each graph. Student t test was used to compare virus titer at each time
point. n.s., nonsigniﬁcant; n.d., not detected. *, P  0.05; ***, P  0.001. (d) Different A549 cell lines were
infected at an MOI of 1 with either VN/1203 wt, VN/1203 ΔF2, PR/8 wt, or PR/8 ΔF2 virus. At the indicated
time point postinfection, cells were lysed and processed through WB.
FIG 5 HAX-1 overexpression inhibits viral replication in an apoptosis-independent manner. (a and b)
Different A549 cell lines were infected at an MOI of 5 for 24 h, collected, and stained for annexin V and
Zombie Red. The percentages of total apoptotic cells (annexin V positive, Zombie positive, and double
positive) are plotted. Values represent means (n  3) with SDs. One-way analysis of variance (ANOVA)
was used to compare samples. *, P  0.05.
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FIG 6 HAX-1 inhibits viral polymerase activity in a PA-dependent manner. (a to d) Mini-replicon assays were performed in A549, H1299, and 293T cells lacking
HAX-1 expression. Cells were transfected with a plasmid carrying a ﬁreﬂy luciferase-based minigenome and one encoding Renilla luciferase under the control
of a constitutive promoter, as well as the following plasmids: 10 ng of pCAGGS.VN-PB2, 10 ng of pCAGGS.VN-PB1, 10 ng of pCAGGS.VN-PA, 20 ng of
pCAGGS.VN-NP, and different amounts of pCAGGS.HAX-1 (a); 10 ng of pCAGGS.PR8-PB2, 10 ng of pCAGGS.PR8-PB1, 10 ng of pCAGGS.PR8-PA, 20 ng of
pCAGGS.PR8-NP, and different amounts of pCAGGS.HAX-1 (b); either 10 ng of pCAGGS.VN-PB2, 10 ng of pCAGGS.VN-PB1, 20 ng of pCAGGS.VN-NP, or 10 ng
of pCAGGS.PR8-PB2, 10 ng of pCAGGS.PR8-PB1, and 20 ng of pCAGGS.PR8-NP with the 10-ng PA segment of either pCAGGS.VN-PA or pCAGGS.PR8-PA and
with or without 500 ng of pCAGGS.HAX-1 (c); and 10 ng of pCAGGS.VN-PB2, 10 ng of pCAGGS.VN-PB1, and 20 ng of pCAGGS.VN-NP with the 10-ng PA segment
of pCAGGS.VN-PA or pCAGGS.BM/1-PA or pCAGGS.Sh/1-PA (d). Cells were lysed 24 h posttransfection, and lysates were subjected to luciferase assay. Values
represent means from triplicate experiments, with SDs. One-way ANOVA was used. **, P  0.01; ***, P  0.001; ****, P  0.0001. Cell lysates were also used
for WB to visualize HAX-1 expression and actin. (e) Different A549 cell lines were infected at an MOI of 0.01 with either Wy/03 wt or Wy/03 ΔF2 virus with
TPCK-treated trypsin at 0.1 g/ml. Supernatants were collected at the indicated time point postinfection, and virus titer was assessed by plaque assay on MDCK
cells. Bars represent means (n  3), with SDs.
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restriction, while human-adapted viruses are insensitive and do not require PB1-F2 to
counteract HAX-1.
HAX-1 interacts with the PA subunit of the IAV polymerase. The main role of PA
for viral replication is providing capped primers for viral mRNA synthesis via endonu-
cleolytic cap snatching (23). This process initiates viral transcription in the nucleus.
Nevertheless, PA was also found to localize to the cytoplasm, probably independently
of the other components of the viral polymerase complex (24), with yet unclear
function. To study the interaction of PA with HAX-1 in a more detailed manner, we ﬁrst
performed pulldown experiments. Surprisingly, both H1N1 and H5N1 PA interact with
HAX-1 (Fig. 7a).
Then we checked in which subcellular compartment H1N1 and H5N1 PAs interact
with HAX-1. We transfected HeLa cells with the following proteins alone or in combi-
nation: HAX-1, VN/1203 PA, and PR/8 PA (Fig. 7b). We observed that both the PAs of
VN/1203 and PR/8 colocalize with HAX-1 in the cytoplasm. Interestingly, we found that
HAX-1 also colocalizes with H5N1 PA in nuclear foci in about 60% of doubly transfected
cells, while HAX-1 is present in nuclear foci in only 20% of cells doubly transfected with
H1N1 PA and HAX-1 (Fig. 7c). When expressed alone, HAX-1 predominantly localizes to
the mitochondria but can be found in the nuclei of some cells (about 20%) (Fig. 7d).
PB1-F2 competes directly with PA for HAX-1 binding. Finally, we aimed at
understanding mechanistically how PB1-F2 overcomes the restriction of PA by HAX-1 in
H5N1-infected cells. Using the same mini-replicon approach as described above, we
could show that PB1-F2 partially restores polymerase function when coexpressed with
HAX-1 (Fig. 8a). Expression of PB1-F2s from PR/8 (H1N1) and the zoonotic H7N9
A/Shanghai/1/2013 did not restore polymerase function of H5N1 polymerase in the
presence of HAX-1 (Fig. 8b). Mechanistically, the simplest model would describe a direct
competition of H5N1 PB1-F2 and PA for HAX-1 binding. In order to support this model,
we overexpressed all three proteins and pulled down PA. We demonstrated that
VN/1203 PA interacts with HAX-1 and that this interaction is diminished by about 80%
in the presence of VN/1203 PB1-F2 (Fig. 8c; average from three independent pulldown
experiments). This result suggests that PB1-F2 replaces PA at the HAX-1 binding site,
thus allowing the release of the polymerase subunit from HAX-1 inhibition.
DISCUSSION
IAV is a highly adaptive organism, capable of adjusting to a diverse group of host
organisms (25). Adaptation to new host species requires adjustments of virus host
interfaces on potentially each level of viral replication. Consequently, zoonotic trans-
mission of IAV between very distantly related hosts, such as domestic bird species and
humans, requires substantial mutagenesis (reviewed in reference 26). At the level of the
viral polymerase complex the differences in host adaptation become especially obvious
(27). Avian IAV polymerase complexes tend to show reduced functionality in human
cells and vice versa (28). Adaptive mutations in all three subunits and nucleoprotein
(NP) of avian IAV polymerase complexes were identiﬁed (27–32). Mehle and colleagues
showed that replacement of an avian virus PA with a human virus PA gives a critical
replication advantage for avian virus in mammalian cells (32). The driving forces behind
most of these changes are likely incompatibilities with required host factors or speciﬁc
restriction factors. Species-speciﬁc sensitivity of viral polymerase complexes was pre-
viously described for myxovirus resistance A (MxA), probably the most potent mam-
malian interferon-stimulated gene (ISG) product acting predominantly against poorly
adapted avian IAVs (33). In contrast to MxA, HAX-1 is not a classical ISG product but
rather is constantly expressed at a fairly high level in a wide range of tissues, including
lungs (34). HAX-1 was extensively studied in the context of calcium signaling and was
shown to prevent ER stress-induced apoptosis (21; reviewed in references 35 and 36).
Interestingly, a number of proteins encoded by viruses other than IAV were shown to
interact with HAX-1 and were implicated in modulating apoptotic host responses in this
way (37–39).
HAX-1 was previously described to antagonize the PA subunit of IAV (15). Although
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that study used A/WSN/1933, a mouse-adapted H1N1 strain, the authors observed a
subtle (2-fold) reduction in viral replication in the presence of endogenous levels of
HAX-1 compared to HAX-1 knockdown H1299 cells. We conﬁrmed these ﬁndings using
a clean knockout approach; however, in contrast to the initial study, we found a
substantial increase in virus-induced apoptosis in HAX-1 knockout cells. This is in line
with the antiapoptotic role described for HAX-1 but contradicts the study by Hsu et al.
FIG 7 HAX-1 interacts with the PA subunit of the polymerase. (a) 293T cells were transfected with each indicated protein cloned into the mammalian expression
plasmid pCAGGS.V5-HAX-1 and pCAGGS.Flag-VN-PA. Cell lysates were collected 48 h later and processed through immunoprecipitation using a monoclonal
antibody against Flag-tagged proteins. Samples were then analyzed by Western blotting. (b) HeLa cells were transfected with V5-HAX-1 and Flag-PA proteins
from either VN/1203 or PR/8. Cells were ﬁxed at 48 h and processed for detection of HAX-1 (red) and PA (green) by immunoﬂuorescence and stained with DAPI.
An asterisk indicates cells where HAX-1 is present in the cytoplasm. (c and d) Graphs represent the percentages of cells where HAX-1 localizes to the nucleus.
Bars represent the means, with SEMs (n  25). (c) In samples transfected with both HAX-1 and PA, we took into account cells that were doubly positive.
*, P  0.05. (d) In samples transfected with HAX-1 only, we took into account every HAX-1-positive cells.
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(15). Apoptosis can have a positive effect on release of viral RNPs from the nucleus,
potentially by activation of host caspases and cleavage of nuclear pore complexes (22);
this might explain the generally increased replication of both human and avian IAV in
HAX-1 knockout cells. Consequently, we cannot rule out that in these cells apoptosis
indeed plays a role in the enhanced replication of all viruses tested in this study,
independent of their sensitivity to HAX-1.
Our data further indicate that the localization of HAX-1–PA interaction might be key
to understanding its speciﬁcity. While H1N1 PA interacts with HAX-1 predominantly in
the cytoplasm, avian H5N1 PA forms foci with HAX-1 in the nucleus, the compartment
of viral transcription and replication. The nature of these foci requires further investi-
gation. For H1N1, we postulate that a proportion of PA might retain HAX-1 in the
cytoplasm, preventing it from interacting with the replication process in the nucleus,
while H5N1 PA translocates to the nucleus with HAX-1. Sequence differences in PA of
PR/8 or VN/1203 might explain this difference in viral sensitivity to HAX-1. A number of
residues in avian polymerase subunit PA were identiﬁed to change upon viral adapta-
tion to human host cells. Bussey and colleagues identiﬁed two residues in the
N-terminal part of the PA of 2009 H1N1 PA that enhance viral polymerase activity in
mammalian cells (30). This PA is of avian origin but likely adapted to a mammalian host
due to the long prevalence in the swine host (40).
FIG 8 PB1-F2 relieves HAX-1 inhibition of PA by competing out their interaction. (a and b) Mini-replicon assay was performed
in A549 HAX KO cells. Subconﬂuent cells were transfected with a plasmid carrying a ﬁreﬂy luciferase-based minigenome and
one encoding Renilla luciferase under the control of a constitutive promoter, as well as the following plasmids: 40 ng of
pCAGGS.VN-PB2, 40 ng of pCAGGS.VN-PB1, 40 ng of pCAGGS.VN-PA, 80 ng of pCAGGS.VN-NP, and, when indicated, 500 ng
of pCAGGS.VN-PB1-F2 and 250 ng of pCAGGS.HAX-1 (a) and 40 ng of pCAGGS.VN-PB2, 40 ng of pCAGGS.VN-PB1, 40 ng of
pCAGGS.VN-PA, 80 ng of pCAGGS.VN-NP, and, when indicated, 250 ng of pCAGGS.HAX-1 and PB1-F2 from different virus
strains, pCAGGS.PR8-PB1-F2, or pCAGGS.Sh/1-PB1-F2 (b). Cells were lysed 24 h after transfection, and lysates were subjected
to luciferase assay. Values represent means from duplicate experiments, with SDs. One-way ANOVA was used. *, P  0.1; **,
P  0.01; ****, P  0.0001. Cell lysates were also used for WB to visualize HAX-1 expression and actin. (c) 293T cells were
transfected with each indicated protein cloned into the mammalian expression plasmid pCAGGS. Cell lysates were collected
48 h later and processed through immunoprecipitation using a monoclonal antibody against Flag-tagged proteins. Samples
were then analyzed by Western blotting. The Western blot shown is representative of three experiments. The graph represents
the relative amounts of HAX-1 bound to PA in the presence or absence of PB1-F2. Means were compared with Student t test.
**, P  0.01 (n  3).
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When trying to determine how certain viruses (such as zoonotic H5N1 strains)
overcome this restriction, we found that PB1-F2, an accessory peptide highly prevalent
in avian IAV, binds to HAX-1 and compensates the restriction of PA in the mini-replicon
assay. H1N1 PB1-F2 did not rescue HAX-1-dependent suppression of PA. Surprisingly,
the same was true for a second zoonotic virus, H7N9. It could be that zoonotic H7N9
viruses found alternative strategies to circumvent innate restriction of the polymerase
complex through the mammalian host. Mazur and colleagues showed enhanced IAV
polymerase function in the presence of PB1-F2, supposedly the result of interaction
with free PB1 (41). This effect was later shown to be limited to the A/Puerto/Rico/8/1934
polymerase complex (42) and does not appear to play a role in the function of PB1-F2
proposed here.
Full-length PB1-F2 is expressed not only in pathogenic H5N1 and low-pathogenicity
H7N9 isolates but also in reassortant pandemic IAV (e.g., 1918 H1N1, 1957 H2N2, and
1968 H3N2). However, it should be noted that at least in the 1957 and the 1968
pandemics, the PA segment was provided by a circulating human strain. We thus
speculate that it was already adapted to human host restriction factors, such as HAX-1.
The 2009 H1N1 pandemic virus has a very special reassortment history (43). While the
PA segment is of avian origin, it does not contain a full-length PB1-F2 ORF. Potentially,
the extended passage history in swine hosts allowed an adaptation to mammalian
restriction factors. A reintroduction of PB1-F2 into this virus did not result in a
replication advantage in human cells. It would be interesting in this context to test if
swine HAX-1 can restrict avian virus PAs.
In our study, we demonstrated that PB1-F2 of H5N1 IAV interferes with the anti-IAV
polymerase function of HAX-1 by competing with PA for HAX-1 binding. Binding of
H5N1 PB1-F2 to HAX-1 would consequently free PA to perform its critical function for
the viral polymerase. Our confocal IF pictures indicate that the PB1-F2 HAX-1 interac-
tion likely takes place at the mitochondria, thus retaining HAX-1 apart from the nucleus.
Obviously, it would be of great importance to study the localization of HAX-1, PB1-F2,
and PA in the context of infection. Unfortunately, the lack of high-quality antibodies for
the viral components (and low expression of these) prevented us from doing these
experiments. Interestingly, all published functions of PB1-F2 seem to be executed
largely by the C-terminal domain (44), the very same domain which interacts with
HAX-1. Additional work is required to understand how the different functions proposed
for PB1-F2 in viral pathology are connected.
In summary, our study provides evidence that the accessory protein PB1-F2 is
required in zoonotic avian viruses, such as highly pathogenic H5N1 isolates, to over-
come the restriction of the viral polymerase subunit PA by human HAX-1.
MATERIALS AND METHODS
Cells. A549 cells (adenocarcinomic human alveolar basal epithelial cells; ATCC), A549-derived cells,
and HeLa cells (adenocarcinomic human cervix epithelial cells; ATCC) were grown in DMEM/F-12
(Dulbecco’s modiﬁed Eagle medium, nutrient mixture F-12; Gibco). HEK 293T (human embryonic kidney;
ATCC), H1299 (human non-small cell lung carcinoma), and MDCK (Madin-Darby canine kidney; ATCC)
cells were grown in DMEM (Gibco). Cell culture media were supplemented with 10% (vol/vol) heat-
inactivated fetal bovine serum (Gibco) and 1% (vol/vol) penicillin-streptomycin (Pen-Strep). Cells were
maintained at 37°C with 5% CO2 and 90% humidity.
Plasmids. pDZ plasmids contain a bidirectional expression cassette for a given inﬂuenza A virus gene
segment and have been described previously (45). pCAGGS-based expression plasmids contain protein-
coding sequences under the control of the chicken -actin promoter (46). pMD2.G and psPAX2 were a
gift from Didier Trono (Addgene; plasmid 12259).
pLVX-IRES-ZsGreen and pLVX-IRES-Puro were purchased from Clontech (respectively, 632187 and
632183). pSpCas9(BB)-2A-GFP (PX458) was a gift from Feng Zhang (Addgene; plasmid 48138) (47).
BiFC expression plasmids for split-YFP were described previously (20). pmTurquoise2-Mito and
pmTurquoise2-ER were a gift from Dorus Gadella (Addgene; plasmids 36208 and 36204, respectively)
(48).
Antibodies. Antibodies for immunoblotting and immunoﬂuorescence included mouse anti-actin-
horseradish peroxidase (anti-actin-HRP; Abcam; ab49900), rabbit anti-HAX-1 (Abcam; ab137613), rabbit
anti-inﬂuenza virus NP (Thermo Fisher; 32242), mouse monoclonal antibody against inﬂuenza A virus M1
(Bio-Rad; MCA401), mouse anti-Flag-HRP (Sigma; A8592), mouse anti-V5 (Invitrogen; R960-25), and rabbit
anti-H5N1 PB1-F2 clone 9947, described previously (8).
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Oligonucleotides. Oligonucleotides for site-directed mutagenesis were purchased from Microsynth
(France) and included the following: VN/1203_C153G_fw (CACCATGGACACAGTGAACAGAACACACCAAT
ATTC) and VN/1203_C153G_rev (GAATATTGGTGTGTTCTGTTCACTGTGTCCATGGTG), VN/1203_C222G_fw
(CTGGAGCACCCCAACTGAACCCGATTGATGGACC) and VN/1203_C222G_rev (GGTCCATCAATCGGGTTCAG
TTGGGGTGCTCCAG), PR/8_C153G_fw (CACCATGGATACTGTGAACAGGACACATCAG) and PR/8_C153G_rev
(CTGATGTGTCCTGTTCACAGTATCCATGGTG), PR/8_C222G_fw (GGAGCACCGCAACTGAACCCGATTGATG
GGC) and PR/8_C222G_rev (GCCCATCAATCGGGTTCAGTTGCGGTGCTCC), Wy/03_C153A_fw (CACCATGG
ACACAGTAAACAGAACACACC) and Wy/03_C153A_rev (GGTGTGTTCTGTTTACTGTGTCCATGGTG), and Wy/
03_C222A_fw (GGGGCACCCCAACTAAACCCAATTGATGGAC) and Wy/03_C222A_rev (GTCCATCAATTGGG
TTTAGTTGGGGTGCCCC).
Viruses. Recombinant viruses were produced using the eight-plasmid rescue system (45). Brieﬂy,
35-mm dishes of subconﬂuent 293T cells were transfected with 0.5 g of each pDZ plasmid using
Lipofectamine 2000 transfection reagent (Thermo Fisher). Twenty-four hours posttransfection, 200 l of
293T supernatant was used to infect 10-day-old chicken eggs. Allantoic ﬂuids were harvest 44 h
postinfection. Unique viral clones were isolated after plaque assay on MDCK cells and grown in eggs, and
their genomes were fully sequenced. In this study, we used a low-pathogenicity H5N1 virus (A/Viet
Nam/1203/04, Halo [18]), an H1N1 virus (A/Puerto Rico/8/1934), and a human H3N2 virus (A/Wyoming/
03/2003). The PB1-F2 mutants of those viruses were generated by introduction of two stop codons (by
replacing C153 with G or A and C222 with G or A) by site-directed mutagenesis using the pairs of
oligonucleotides listed above. These changes do not affect the amino acid sequence of PB1. The
introduction of the mutation was veriﬁed by sequencing, and its efﬁciency was assessed by Western
blotting (WB) using polyclonal rabbit serum against PB1-F2 (8).
Mass spectrometry. Fifteen 10-cm dishes of 293T cells were transfected with 25 ng of pCAGGS.Flag-
VN.PB1-F2 each using Lipofectamine 2000. Twenty-four hours posttransfection, cells were infected with
A/Viet Nam/1203/2004 (Halo) PB1ΔF2 at a multiplicity of infection (MOI) of 1. Cells were collected 8 h
postinfection by scraping, washed in phosphate-buffered saline (PBS), pelleted, and lysed in 20 ml of cold
lysis buffer (0.25% [vol/vol] NP-40, 50 mM Tris-HCl [pH 7.5], 200 mM NaCl, 1 mM EDTA, protease,
phosphatase, inhibitors, and N-ethylmaleimide [NEM]). Cells were mechanically disrupted with a Dounce
homogenizer and sonicated with a Bioruptor at 4°C for ﬁve cycles (30 s on and 30 s off). Insoluble material
was removed by centrifugation at 15,000 rpm for 20 min. The supernatant was precleared with
nonspeciﬁc beads for 3 h at 4°C. The precleared lysate was mixed with 50 l of beads coupled to anti-Flag
(Dynabeads, M2; Sigma) and immunoprecipitation (IP) was performed for 3 h at 4°C. Beads were then
washed four times with cold buffer (50 mM Tris-HCl [pH 7.5], 200 mM NaCl, 0.25% NP-40, and 1 mM
EDTA) and two times with detergent-free buffer to avoid interference with mass spectrometry analysis.
Beads were eluted three times with 3Flag peptide (Sigma) in a buffer of 50 mM Tris-HCl (pH 7.5) and
200 mM NaCl. The eluted material was subjected to acetone precipitation. Resuspended proteins were
digested with trypsin and then analyzed via mass spectrometry. For the identiﬁcation of PB1-F2-speciﬁc
interactors, we ﬁrst excluded proteins precipitated from cells transfected with empty vector (see Table
S2 in the supplemental material [based on area score]). The remaining proteins were ﬁltered against the
CRAPome database (49). The resulting score indicates the number of published experiments in which a
target protein was pulled down with a speciﬁc antigen tag (Flag in this study). Consequently, the lower
this score, the higher the chance for a speciﬁc pulldown.
Generation of a KO cell line using CRISPR/Cas9. Subconﬂuent A549, 293T, or H1299 cells in 35-mm
dishes were transfected with 1 g of plasmid pSP.Cas9wt.GFP or pSP.Cas9wt.GFP.HAX1sgRNA2.3 using
3 l of Trans-IT LT1 (Mirus) according to the manufacturer’s protocol. Seventy-two hours posttransfec-
tion, green ﬂuorescent protein (GFP)-positive cells were sorted and seeded at 100 per 10-cm dish.
Fourteen days later, colonies grown from single cells were picked and expanded. The efﬁciency of
knockout was assessed by Western blotting. Cells generated using a guide RNA directed against HAX-1
are named A549 HAX KO and those using a random guide RNA are named A549 ctrl 2.
Generation of overexpressing cell lines with lentivirus. Subconﬂuent 293T cells were transfected
at a ratio of 1:3:4 with the following plasmids: pMD2.G (vesicular stomatitis virus G protein [VSV-G]),
psPAX2 (HIV gag-pol), and pLVX.HAX1.IRESpuro or pLVX.ZsGreen.IRESpuro using 2 l/g of DNA of
Trans-IT LT1 (Mirus) according to the manufacturer’s protocol. Twenty-four hours posttransfection, 293T
medium was replaced with target cell medium. Target cells (A549) were seeded in a 6-well plate at
subconﬂuent density (50%). At 48 h posttransfection, the 293T cell supernatant containing lentiviruses
was harvested with a syringe and pressed slowly through a 0.44-m sterile ﬁlter. The ﬁltered supernatant
was complemented with 8 g/ml of Polybrene. Target cells were washed one time with PBS before
addition of 2 ml of the supernatant-Polybrene mixture. Four hours after infection with lentiviruses, the
293T cell supernatant was removed from target cells and replaced with the appropriate medium. Two
days postinfection, target cells were split and subjected to selection using puromycin at 2 g/ml. The
efﬁciency of overexpression was assessed by WB. Cells generated using a vector expressing HAX-1 are
named A549 HAX OE, and those using an empty vector are named A549 ctrl 1.
Viral growth kinetics. Different A549 cell lines were seeded in 12-well plates at subconﬂuent density
(80%) and infected with each virus at an MOI of 0.01 in triplicate in the presence of L-1-tosylamide-2-
phenylethyl chloromethyl ketone TPCK-treated trypsin (Sigma; T1426). Supernatants were collected at
the desired time postinfection. Virus titers were determined by plaque assay in MDCK cells.
Plaque assay. A conﬂuent monolayer of MDCK cells was infected with 200 l of serially diluted virus.
Viruses were diluted in PBS–0.2% (wt/vol) bovine serum albumin (BSA) (Millipore; 126579). Forty-ﬁve
minutes postinfection, the inoculum was removed and an agarose overlay (ﬁnal concentrations: 1
minimal essential medium [MEM], 1% agarose, 100 mM L-glutamine, 2.5% sodium bicarbonate, 0.5 M
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HEPES, 5 mg/ml of Pen-Strep, 0.2% BSA, and 0.01% DEAE-dextran) was added. Cells were incubated at
37°C for 48 h. Then cells were ﬁxed in formaldehyde, the overlay was removed, and the cell monolayer
was stained with a solution of crystal violet.
IP assay. Subconﬂuent 293T cells (35 mm dish) were cotransfected with 1 g of each plasmid using
2 l/g DNA of Trans-IT LT1 (Mirus) according to the manufacturer’s protocol. Forty-eight hours
posttransfection, cells were washed twice in cold PBS and then lysed on ice with 300 l of IP lysis buffer
(50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.5 mM EDTA, 0.5% [vol/vol] NP-40) with protease inhibitors
(Pierce; 88266). Samples were sonicated twice for 10 s using a microtip (output, 6 to 9 W). Insoluble
material was removed by centrifugation for 20 min at 10,000 relative centrifugal force (rcf) and 4°C. Fifty
microliters of the cleared lysate was mixed 1:1 with urea disruption buffer (6.25 M urea, 15% [vol/vol]
-mercaptoethanol, 4.5% [wt/vol] SDS, and 0.1% bromophenol blue) to serve as a cell lysate control,
while the remaining 200 l was processed for immunoprecipitation using anti-Flag M2 afﬁnity gel
(Sigma; A2220). Thirty microliters of agarose beads slurry was washed four times in 1 ml of cold IP lysis
buffer with spin at 4°C for 5 min at 500 rcf. Beads were then resuspended in 800 l of IP lysis buffer with
protease inhibitor, and 200 l of cell lysate was added. The immunoprecipitation was performed
overnight (o/n) at 4°C under constant rotation. Then beads were washed six times in IP lysis buffer.
Samples were kept on ice and tubes were changed after two washes. After the sixth wash, 70 l of urea
disruption buffer was added for 15 min. Samples were heated at 85°C for 5 min and then centrifuged at
10,000 rcf for 10 min. Samples were then used in a Western blot. When mentioned, we performed
sequential IP. In short, 293T cells were transfected with only one plasmid. Twenty-four hours posttrans-
fection, cells were lysed with 300 l of IP lysis buffer with protease inhibitors, sonicated, and centrifuged.
Fifty microliters of the cleared lysate was mixed 1:1 with urea disruption buffer. The ﬁrst round of IP was
performed o/n using 200 l of samples transfected with the bait. The bead-bait complexes were washed
six times and then added in 200 l of samples transfected with the prey for a second round of IP o/n.
The potential bead-bait-prey complexes were washed and disrupted in urea buffer before being
processed through WB.
Immunoﬂuorescence (IF) assay. Subconﬂuent HeLa cells, seeded on glass coverslips (24-well plate),
were transfected with 250 ng of each desired plasmid using 3 l/g of DNA of Trans-IT LT1 (Mirus)
according to the manufacturer’s protocol. Forty-eight hours posttransfection, cells were washed once in
PBS and then ﬁxed in PBS–4% formaldehyde for 30 min. Then cells were washed twice and permeab-
ilized with PBS–0.1% Triton X-100 for 15 min. The PBS-Triton was removed and cells were blocked in
PBA–1% BSA for 1 h. Primary antibody directed against the protein tag was diluted at 1:100 in PBS–1%
BSA and incubated for 1 h 30 min. After three washes in PBS–1% BSA, cells were incubated with a
secondary antibody coupled to Alexa Fluor at 5 g/ml for 1 h in the dark. Cells were washed twice in
PBS–1% BSA and once in PBS before being mounted on a coverslip using Prolong Diamond antifade
mounting medium with or without 4=,6-diamidino-2-phenylindole (DAPI; Thermo Fisher). Pictures were
taken using a confocal microscope (Leica SP5).
Bimolecular ﬂuorescence complementation (BiFC) assay. Subconﬂuent HeLa cells were trans-
fected with 250 ng of each desired plasmid using 3 l/g of DNA of Trans-IT LT1 (Mirus) according to
the manufacturer’s protocol. Forty hours posttransfection, cells were shifted at 33°C for 4 h to stabilize
YFP complexes. Pictures were taken using the EVOS cell imaging system (Thermo Fisher).
Mini-replicon assay. Subconﬂuent A549, 293T, or H1299 cells lacking HAX-1 expression were
cotransfected with expression plasmids for the viral proteins VN PB2, PB1, PA, and NP as well as a plasmid
carrying a ﬁreﬂy luciferase-based minigenome and one encoding Renilla luciferase under the control of
a constitutive promoter (50). The mini-replicon system of A/Viet Nam/1203/2004 (H5N1) and A/Puerto
Rico/8/1934 (H3N2) and pDZ-PA of A/Shanghai/1/2013 (H7N9) were kindly provided by P. Palese (Icahn
School of Medicine at Mount Sinai, New York, NY). pCAGGS-PA of A/Brevig Mission/1/1918 was kindly
provided by M. Schwemmle, University of Freiburg, Germany. When indicated, different amounts of
HAX-1 and/or PB1-F2 protein-coding plasmids were added to the system. Twenty-four hours posttrans-
fection, cells were lysed and the luciferase assay ws performed using a dual-luciferase reporter assay
system (Promega).
Apoptosis assay. Cells were seeded in 12-well plates at subconﬂuent density (70%) and infected
with each virus at an MOI of 5 without TPCK-treated trypsin. Twenty-four hours postinfection, cells were
harvested using trypsin-EDTA and processed through staining for apoptosis markers. For this protocol,
all spins were performed for 5 min at 4°C at 400 rcf and all solutions were used at 4°C unless mentioned
otherwise. Cells were washed twice with 1 ml of PBS, resuspended in 100 l of PBS with 1 l of Zombie
Red ﬁxable viability dye (BioLegend), and incubated 30 min at 4°C in the dark. Then cells were washed
twice with 1 ml of PBS–2% BSA and once with annexin V binding buffer (BioLegend) at room temperature
(RT). Cells were incubated for 15 min at RT with 5 l of annexin V (BioLegend) diluted in 100 l of annexin
V binding buffer. Then cells were washed once in annexin V buffer and once in PBS supplemented with
calcium and magnesium (PBS-Ca-Mg). Cells were ﬁxed in 200 l of 2% formaldehyde diluted in
PBS-Ca-Mg for 20 min at RT. Cells were washed twice in PBS-Ca-Mg and then resuspended in 200 l of
PBS-Ca-Mg. Samples were analyzed by ﬂow cytometry using a Gallios 4 (Beckman Coulter) and results
were analyzed with the software Kaluza Analysis 1.5a.
Statistical analysis. Statistical analysis was performed using GraphPad Prism 6. Statistical tests
applied are indicated in each respective ﬁgure legend.
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